A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.
about
DNA vaccines: designing strategies against parasitic infectionsPrime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future TherapiesThe sentinel within: exploiting the immune system for cancer biomarkers.Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developmentsPreclinical and clinical development of DNA vaccines for prostate cancer.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialMurine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumorStrategies for cancer vaccine development.DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responsesIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancerProposed mechanisms of action for prostate cancer vaccines.Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancerDNA vaccines, electroporation and their applications in cancer treatmentHarnessing DNA-induced immune responses for improving cancer vaccines.Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.Trial watch: DNA vaccines for cancer therapy.Immunotherapy and immune evasion in prostate cancer.State of the art in tumor antigen and biomarker discovery.Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.Sipuleucel-T: immunotherapy for advanced prostate cancer.Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancersDNA Vaccines for Prostate Cancer.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.TAA polyepitope DNA-based vaccines: a potential tool for cancer therapymRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.DNA vaccination for prostate cancer: key concepts and considerations.Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.Immunotherapy for prostate cancer: False promises or true hope?Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals.Prostate cancer vaccines: Update on clinical development.DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?
P2860
Q24801950-81D5E430-FCEB-4CE4-A672-3AE6120E79DEQ24813328-00D20577-665F-4102-B105-EAC6ABD447A4Q26752558-1A14D199-3F03-4968-8649-3F2FBD34A2CCQ33221191-0449E0B9-1498-402A-9883-AF7E923F25B6Q33713435-CBA08024-8F59-45B2-9431-9137358FCE46Q33740811-B8D2AE97-11D0-48CC-8CF6-AC8C96AA309BQ33872776-104AB1B8-2201-4252-85F7-8377599A0CCBQ33991804-381753EA-8A75-43D7-8D4F-53691AE26E9EQ34000082-1B22C7E7-0639-4BB5-9119-579EF9B5CEA0Q34038338-D3B3DF24-3F7C-4629-ADCE-D3B4DA626B00Q34127323-B8740D67-0479-4E56-A70E-37605588BB2EQ34309830-E46E227C-73CD-45C7-BAD3-F08CB6B0EFF1Q34577158-1D75C6F5-2DB1-4EF7-A9FC-74AB02A296DEQ34610121-83134500-DCBE-4152-BEF5-4A29F20AC82DQ35065923-E26016C5-1426-4081-8F3A-C9C22C19597EQ35174754-0AE97D7E-7EE2-4EE1-9876-E320FC6DF7E0Q35218994-7C2B2CA0-8EBA-4FC6-8000-F739792B4390Q36005476-38C2752F-C9CC-4C87-9F83-497FD2821A97Q36256459-5B514A5C-271E-4BC6-B0C5-0B81262148CDQ36694866-94200704-E45D-44B4-B893-800FAD2861D5Q36780146-F2CDD162-42CD-4A8A-A4AD-A33FA1F66EE6Q36845824-A2E81CFB-3F69-4C37-B3D3-379DCE742A84Q37061769-7A7168F8-2F71-4BB7-B7BB-61BD583F5AA8Q37132800-2F489032-6E86-4A72-ADDD-1B7749A67639Q37192915-C5F461B2-9C9F-4590-B427-A3BFB5AA56F6Q37283724-D7E029A4-740F-4CE8-886F-E149E2943EAFQ37325063-6CCF7DE6-E8B8-4325-8D3F-492A80BAAB29Q37455348-A9E7B52E-8924-4813-B95C-353DA7ED35A2Q37589091-FE33BE7D-FFD2-4613-B854-86ABA0308521Q37604481-DA86A9D4-3466-45EC-B786-C5EA9149286AQ37703163-026E52F5-B339-4DB8-BA90-1052CCEFF24FQ37771268-5C69C1C0-90AC-42DA-BD37-01BCD11B690CQ38284699-876709F2-DFCE-4823-BE31-468BC2C3F88DQ38544772-C9E4DF71-C727-4AB3-B611-0624010B5957Q38839675-438EA449-A4E7-4C66-A8BB-9FE586D796CEQ38959645-11DA99EB-941B-446E-B20B-7EB0E1239401Q39666393-FA37AB6B-7898-4E83-AABD-44938B0F63CEQ40353315-0DE49B6B-9640-4465-AD53-364C8A4B61F9Q41220895-4BD4CE1B-DC88-4137-8307-FB2DB0F96F68Q41561252-1DF8DC54-B369-4CB9-B703-A3194BEAA91C
P2860
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A phase I trial of DNA vaccina ...... ne-refractory prostate cancer.
@ast
A phase I trial of DNA vaccina ...... ne-refractory prostate cancer.
@en
type
label
A phase I trial of DNA vaccina ...... ne-refractory prostate cancer.
@ast
A phase I trial of DNA vaccina ...... ne-refractory prostate cancer.
@en
prefLabel
A phase I trial of DNA vaccina ...... ne-refractory prostate cancer.
@ast
A phase I trial of DNA vaccina ...... ne-refractory prostate cancer.
@en
P2093
P2860
P50
P356
P1476
A phase I trial of DNA vaccina ...... one-refractory prostate cancer
@en
P2093
A M Miller
A Palmborg
M Hellström
M Pavlenko
R Kiessling
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602019
P407
P577
2004-08-01T00:00:00Z